On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center
Willem H Collier1, Mark Zobeck2,3, Adam J Esbenshade4
1Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Pediatric Blood & Cancer
|July 25, 2026
Summary
Hierarchical composite endpoints (HCEs) simplify complex pediatric clinical trials by combining multiple outcomes. This approach enhances the detection of treatment benefits and clarifies trial conclusions, even with mixed results.
Area of Science:
- Clinical Trials Methodology
- Pediatric Oncology
- Biostatistics
Background:
- Pediatric supportive care trials frequently assess numerous outcomes, making interpretation challenging.
- Hierarchical composite endpoints (HCEs) offer a structured method to synthesize multiple outcomes based on clinical significance.
Purpose of the Study:
- To evaluate the utility of HCEs in simplifying interpretation and enhancing sensitivity in pediatric supportive care clinical trials.
- To assess the potential of HCEs to harmonize conclusions in trials with both benefits and harms.
Main Methods:
- Post hoc analyses were conducted on two randomized trials from the Children's Oncology Group.
- Hierarchical composite endpoints (HCEs) were applied to integrate multiple key outcomes.
Main Results:
- HCEs demonstrated increased sensitivity in detecting overall treatment benefits compared to individual endpoints.
- HCEs facilitated harmonized trial conclusions, effectively managing scenarios with both intervention benefits and harms.
Conclusions:
- HCEs can improve the interpretability of complex pediatric supportive care trials.
- The prospective use of HCEs in pediatric oncology research warrants consideration for enhanced trial analysis.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...